Two Leading Neuroscientists Join Biogen-Idec to Advance Neurodegenerative Disease Research

Biogen-Idec is taking further steps to advance its research and development efforts in neurodegenerative diseases. After appointing Donald Johns to head the ALS iHUB in August, Biogen has announced that two world renown neuroscientists have joined the company: Dr. Christopher Henderson joins as Vice President of Neurology and Dr. Richard Ransohoff as senior research fellow of neuroimmunology. Dr. Henderson joins Biogen-Idec from Columbia, where he was the co-founder of the Center for Motor Neuron Biology and Disease, and he is the director of TARGET-ALS. Dr. Ransohoff is a leading neuroimmunologist, who joins the company from the Cleveland Clinic, where he directed the Neuroinflammation Research Center. These two outstanding scientists will now focus on advancing Biogen-Idec’s research and drug discovery for neurodegenerative diseases, including ALS.

Biogen-Idec is taking further steps to advance its research and development efforts in neurodegenerative diseases. After appointing Donald Johns to head the ALS iHUB in August, Biogen has announced that two world renown neuroscientists have joined the company: Dr. Christopher Henderson joins as Vice President of Neurology and Dr. Richard Ransohoff as senior research fellow of neuroimmunology. Dr. Henderson joins Biogen-Idec from Columbia, where he was the co-founder of the Center for Motor Neuron Biology and Disease, and he is the director of TARGET-ALS. Dr. Ransohoff is a leading neuroimmunologist, who joins the company from the Cleveland Clinic, where he directed the Neuroinflammation Research Center. These two outstanding scientists will now focus on advancing Biogen-Idec’s research and drug discovery for neurodegenerative diseases, including ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail